 |
|
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):269-272. Published online 2022 Feb 15 DOI: https://doi.org/10.3350/cmh.2022.0040
|
|
Citations to this article as recorded by
 Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials
Mark Lebwohl, Joseph F. Merola, Bruce Strober, April Armstrong, Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk de Cuyper, Nancy Cross, Owen Davies, Alice B. Gottlieb
Journal of the American Academy of Dermatology.2024;[Epub] CrossRef Ultrasonographic Assessment of Tissue Stiffness: Recent Progress in Transient Elastography and Shear Wave Elastography in the Liver and Various Organs
MASAHITO NAKANO, RYOKO KUROMATSU, TAKUMI KAWAGUCHI
The Kurume Medical Journal.2024;[Epub] CrossRef Interleukin‐23 inhibitors decrease Fibrosis‐4 index in psoriasis patients with elevated Fibrosis‐4 index but not inteleukin‐17 inhibitors
Ryosuke Takeshima, Masahiro Kamata, Shoya Suzuki, Makoto Ito, Ayu Watanabe, Hideaki Uchida, Chika Chijiwa, Yoshiki Okada, Saori Azuma, Mayumi Nagata, Shota Egawa, Azusa Hiura, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa
The Journal of Dermatology.2024;[Epub] CrossRef The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro
Hepatology Research.2023; 53(2): 104. CrossRef The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases
Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Nutrients.2023; 15(5): 1123. CrossRef Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?
Yushu Yang, XiaoSong He, Manuel Rojas, Patrick S. C. Leung, Lixia Gao
Frontiers in Immunology.2023;[Epub] CrossRef Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications
Jie Fang, Chen-Huan Yu, Xue-Jian Li, Jin-Mei Yao, Zheng-Yu Fang, Soo-Hyun Yoon, Wen-Ying Yu
Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis
Tanat Yongpisarn, Amornrut Namasondhi, Wimolsiri Iamsumang, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit
Frontiers in Medicine.2022;[Epub] CrossRef
|